文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > 【医脉通
侵权投诉

【医脉通

Carroll et al.

NMO. In this case, however, the patient did not experience a preferential loss of AQP4 in the affected regions.40 Vomiting is also among the listed symptoms, as one study found 40.0% (6/15) of NMO patients to have lesions in the area postrema or medullary floor of the fourth ventricle (regions associated with vomiting control) versus 0% of controls (n=5) or those with MS (n=8).41 In fact, medullary lesions are significantly more common among patients with NMO versus MS (91.3% versus 36.0%, p<0.001).42

SLE and Sjögren’s syndrome have been observed in both NMO43 and MS patients;44 therefore, the presence of either of these comorbidities cannot be relied upon to dis-tinguish the two inflammatory demyelinating disease pro-cesses. However, this does not mean that early treatment cannot be initiated. Rather, we propose that a patient with an idiopathic inflammatory demyelinating disease but lack-ing diagnostic evidence of underlying MS, who has been clinically diagnosed with SLE or Sjögren’s syndrome, is unlikely to benefit from first-line DMT.

Individuals in whom a positive anti-AQP4 antibody/NMO-IgG assay is found, as measured by a validated labo-ratory, are unlikely to benefit from first-line DMT; rather the use of more aggressive NMO-associated therapies is war-ranted. In fact, NMO diagnostic criteria were revised in 2006 to reflect the high specificity of these antibodies in distinguishing NMO from other inflammatory demyelinat-ing disease processes.33 Given variations in the sensitivity, reliability and fidelity with which anti-AQP4 antibodies/NMO-IgG are measured, the use of validated laboratories with high sensitivity is stressed. Particular clinical indica-tors warranting anti-APQ4 antibody/NMO-IgG testing include a patient presenting with isolated or relapsing myeli-tis, optic neuritis or an optic-spinal phenotype. It should be noted that anti-AQP4 antibodies/NMO-IgG have been detected in SLE or Sjögren’s syndrome patients, but only in those with concurrent optic neuritis or myelitis.43,45 Such patients are likely to have an NMO spectrum disorder;46 as a consequence, they should be treated aggressively for NMO, as summarized briefly below and reviewed thor-oughly in Carroll and Fujihara.12

As the accumulation of disability with NMO (or an NMO spectrum disorder) can be severe and rapid, if an NMO attack or relapse is suspected then concomitant treatment with high-dose methylprednisolone (HDMP) (3–5 days) and plasma exchange (five treatments over 10 days) is recommended. Physicians should feel comforta-ble using HDMP to treat NMO relapses or attacks, as the regimen is identical to that given to MS patients.12 Because HDMP is considered by some to be less effective in NMO than MS, plasma exchange (with a success rate of approx-imately 50%) could be administered in parallel.12 Together, these therapies suppress inflammation (via effects on both immune cells and cytokine cascades), stabilize the blood-brain barrier, reduce edema and remove auto-reactive anti-bodies.12 Lymphocytapheresis may also offer benefits.47

1373

To prevent future NMO relapses, physicians could admin-ister immunosuppressive drugs, such as azathioprine or mycophenolate mofetil with or without corticosteroids (prednisolone). Certain B-cell–targeting antibodies (e.g. rituximab) have also been used because of the presumed role of these immune cells in NMO pathology.48 These treatment recommendations are based on anecdotal evi-dence and expert opinion because controlled treatment tri-als are lacking in patients with NMO.12

Category 2. Patients in whom first-line MS DMT may be administered and who require careful monitoring

In patients who present with any of the following at diagno-sis or during follow-up, first-line MS DMT may be initi-ated, but careful monitoring is required:

Clinical and laboratory features

○ Severe acute myelopathy, with residual deficit○ Recurrent myelopathy or recurrent optic neu-ropathy alone

○ Cerebrospinal fluid (CSF) hypercellularity (>50 cells/mm3)

○ CSF neutrophilic pleocytosis (>5 cells/mm3)○ Seropositivity for SLE or Sjögren’s syndrome Brain MRI features

○ Bilateral hypothalamic lesions

○ Bilateral or longitudinal corticospinal tract lesions

○ Non-enhancing tumefactive cerebral lesion(s) suggestive of vasogenic edema

○ ‘Cloud-like’ gadolinium enhancement (multifo-cal or patchy enhancement with blurred margins)○ Normal appearanceThe features selected for this patient category are not typical for MS, thus raising suspicion of an alternative inflammatory demyelinating disease process. CSF cell counts >50 cells/mm3 accompanied by neutrophilia (>5 cells/mm3) have been measured in patients with NMO37,49 and in patients presenting with idiopathic inflammatory demyelinating disease characterized by optic nerve and spinal cord lesions, particularly during the acute phase.50 In one study, only 2.2% of Japanese patients with clini-cally definite MS (Poser criteria) experienced CSF pleo-cytosis versus 25% of those with idiopathic inflammatory demyelinating disease marked by the presence of optic nerve and spinal cord lesions.51

Although brain lesions are more common to MS than NMO, the brain lesions present in patients with NMO are generally of a different nature. Firstly, for example, bilateral hypothalamic lesions, which can cause clinical signs such as narcolepsy52,53 (Figure 1), have a tendency in the acute stage to be edematous, large and contrast-enhancing in NMO, but

上一页第3页

你可能喜欢

热门文档

相关文档

  • 【医脉通

    【医脉通_临床医学_医药卫生_专业资料。心电与循环 2014 年第 33 卷第 6 期 欧美肺动脉高压诊疗指南解读郭航远 郭航远 , 浙江 大学 绍兴 医院 (绍兴 市人民...

  • 【医脉通

    【医脉通_临床医学_医药卫生_专业资料。2015 ADA /EASD 2 型糖尿病管理指南概要(编译) 2015.1.28 近年随着降糖药物种类增多,临床医生在选择与应用降糖药物方面存...

  • 【医脉通

    【医脉通_基础医学_医药卫生_专业资料。网络出版时间:2014-12-04 16:57 网络...骨髓间充质干细胞移植对胆道缺血性狭窄的防治作用研究[J].中国普 通外科杂志,...

  • 【医脉通

    【医脉通_临床医学_医药卫生_专业资料。临床指南中国原发性肺癌诊疗规范( 2015 年版)一、概述(一)前言 原发性肺癌 (以下简称肺癌)是我国最常见的恶性肿瘤之一。...

  • 【医脉通

    【医脉通_临床医学_医药卫生_专业资料。中华妇幼临床医学杂志 ( 电子版 )201 4年1 2 月第 10 卷第 6期 ·733· · 标准 · 方案 · 指南 · 儿童过敏...

  • 【医脉通

    【医脉通_临床医学_医药卫生_专业资料。主堡』L型盘查!!!篁!旦筮!!鲞筮!翅垦!i!』里型堕!,』!!!盟!Q!!:∑!!:!!:塑!:! .标准.方案.指南. 儿童...

  • 【医脉通指南频道】2014+胸痛规范化评估与诊断中国专家...

    医脉通临床指南 http://guide.medlive.cn/ 胸痛规范化评估与诊断中国专家共识胸痛是一种常见的临床症状,病因繁杂,涉及多个器官和系统,病情程度轻重不一,规范 化...

  • 【医脉通

    【医脉通_临床医学_医药卫生_专业资料。D 6 专题 2014 年 12 月 4 日 星期四 计, 2013 年报告的丙肝患者超 20 万, 较 2005 年增加约 3 倍。而大部分...

  • 【医脉通

    【医脉通_临床医学_医药卫生_专业资料 暂无评价0人阅读0次下载举报文档 【医脉通_临床医学_医药卫生_专业资料。中国实用外科杂志 2015 年 1 月第 35 卷...

  • 【医脉通

    【医脉通_临床医学_医药卫生_专业资料 暂无评价0人阅读0次下载举报文档 【医脉通_临床医学_医药卫生_专业资料。< W $3 G/ 1T " FG@ G7 , < 7 "...

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email